Company:  SIGA TECHNOLOGIES INC (SIGA)
Form Type:  10-Q
Filing Date:  11/6/2013 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
 
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.88  
Change: 
0.075 (2.68%)  
Trade Time: 
Sep 23  
Market Cap: 
$156.07M
Trade SIGA now with 

© 2016  
Description of Business
We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX(TM), also known as Tecovirimat or ST-246®, an orally administered antiviral drug that targets orthopoxvirus infections. While TPOXX(TM) is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being developed with support from BARDA and delivered to the Strategic Stockpile under Project BioShield. BARDA Contract - TPOXX(TM), also known as Tecovirimat or ST-246® On May 13, 2011, the Company signed the BARDA Contract pursuant to which we agreed to deliver two million courses of TPOXX(TM) to the Strategic Stockpile. The BARDA Contract is worth approximately $470 million, including $409.8 million for manufacture and delivery of 1.7 million courses of TPOXX(TM) and $60 million of potential reimbursements related to development and supportive activities (the "Base Contract").
Register and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1 - Condensed Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sale of Equity Securities and Use of ...
      Item 3. Defaults upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 31.2
    Certification by Chief Financial Officer Pursuant to
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO